MedTech startups die in the gap between regulatory spend and revenue. The spend starts 12 to 18 months before first sale. Notified Body application fees, testing labs, CER consultants, QMS implementation. And peaks during the Article 52 conformity assessment. Revenue starts after CE mark. The founders who survive the cash trough are the ones who mapped it in advance and funded through it.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • The MDR conformity assessment under Article 52 and Annex IX is a long, expensive, front-loaded process. Cash out starts long before cash in.
  • Typical Class IIa or IIb regulatory cost profile: QMS implementation, NB application, testing, CER, and audit fees spread across 12–18 months of zero revenue.
  • Notified Body fee structures are usually milestone-based with deposits payable before work starts. Plan working capital around the NB invoice schedule, not the calendar quarter.
  • Supplier terms, test lab pre-payments, and CRO milestones compound the cash strain and do not respect your runway model.
  • Every MedTech startup hits a cash trough somewhere between technical documentation finalisation and CE certificate issuance. Founders who raise 20–30% of regulatory budget as contingency survive; those who raise exactly to plan rarely do.

Why this matters

Every MedTech founder we have worked with has underestimated one specific thing: the compounding cost of time during the regulatory phase. Not the total cost. Most founders budget the headline number reasonably well. The timing. The rhythm of when the cash leaves the account versus when it comes back.

Felix has coached 44 startups. The recurring failure mode is not a team that cannot build a product. It is a team that built a good product, raised what looked like enough money, and ran out of cash six weeks before certificate issuance because the Notified Body surveillance fee arrived when they thought they had already finished paying. In MedTech, the treasury function is a survival function.

This post is about mapping the cash trough before you fall into it.

What MDR actually says

Article 52. Conformity assessment routes

MDR Article 52 lays out the conformity assessment procedures available by device class. For Class I devices that are not sterile, without a measuring function, and non-reusable surgical instruments, the manufacturer self-certifies without NB involvement. For all other classes, NB involvement is required through one of the procedures in Annexes IX, X, or XI. Annex IX. The most common full QMS plus technical documentation route. Is what drives the cash profile for most startups.

The MDR does not dictate fee schedules or payment terms; those are set by each Notified Body commercially. But Article 52 does require a process that takes real calendar time. QMS audit, technical documentation assessment, and (for higher classes) unannounced audits under Article 52(3). The time is the cost, because the team burn continues through it.

Annex IX. QMS and technical documentation assessment

Annex IX describes the full QMS assessment plus technical documentation assessment. The manufacturer submits an application, the NB reviews the QMS and conducts on-site audits, the NB assesses technical documentation for at least one representative sample per device category (or per device for certain classes), and the NB issues the certificate upon successful completion. Every step in this sequence corresponds to an invoice.

Article 52(3) adds periodic surveillance at least every 12 months and unannounced audits at least once every five years for many device categories. Costs that continue for the lifetime of the certificate, not just until issuance.

A worked example

A three-person Class IIb startup developing an implantable sensor plans a 24-month path from seed close to CE mark. The founders raise EUR 2.4 million. Their pitch deck shows regulatory spend at EUR 650,000. Here is how the cash actually moves.

Months 1–6. QMS implementation begins. EUR 45,000 in consulting for procedure writing. Team burn at EUR 90,000/month, so EUR 540,000 for the period. QMS software at EUR 25,000/year. Cash spent: EUR 612,000. Revenue: zero. Cash remaining: EUR 1,788,000.

Months 7–12. Technical file drafting, bench testing, biocompatibility under EN ISO 10993-1:2025. Testing lab pre-payments EUR 95,000. Risk management work. Team burn EUR 540,000. Clinical evaluation consulting starts at EUR 55,000. NB selection complete, application deposit EUR 35,000. Cash spent in period: EUR 725,000. Revenue: zero. Cash remaining: EUR 1,063,000.

Months 13–18. Notified Body Stage 1 audit, followed by Stage 2 audit. NB audit fees EUR 75,000 across both stages. Technical documentation review begins with additional NB fees EUR 90,000. Clinical investigation feasibility work at EUR 40,000 even though they concluded equivalence was not available. Team burn EUR 540,000. Cash spent: EUR 745,000. Revenue: zero. Cash remaining: EUR 318,000.

Months 19–24. Non-conformities raised during Stage 2 audit. Six weeks of CAPA work. Re-submission. Additional NB review fees EUR 35,000. Certificate finally issued month 22. First customer contract month 23, payment terms net 60. Team burn EUR 540,000. Launch marketing EUR 60,000. Cash spent: EUR 635,000. Revenue collected in period: EUR 40,000. Cash remaining: EUR −277,000.

The founders are cash-negative on month 22 of the plan, three weeks after CE issuance. They bridge with a convertible note at punitive terms because they have no leverage. Everything in the regulatory plan went roughly right. The cash trough killed them anyway because they treated the regulatory budget as a calendar-linear line item instead of a lumpy, milestone-driven series of large invoices.

The Subtract to Ship playbook

1. Build a regulatory cash flow map, not a regulatory budget. A budget is a single number. A cash flow map is a 24-month spreadsheet with every NB invoice, every lab pre-payment, every consultant milestone, and every team burn month. The spend is lumpy. Model it lumpy.

2. Get the NB fee schedule before you sign. Notified Body contracts include a fee schedule that shows application fee, Stage 1 audit, Stage 2 audit, technical documentation review per category, certificate issuance, annual surveillance, and unannounced audits. Many founders receive this document, file it, and never model it. Model it. Put each line on the month you expect it to be invoiced. The NB will not wait.

3. Negotiate supplier and lab terms aggressively. On timing, not just price. Test labs often demand 50% on order and 50% on sample receipt. CROs often demand milestone payments. Suppliers of critical components may offer net 30 to net 60 once you are a known customer, but only after the first order. Every day of payment terms you can buy delays cash out.

4. Raise 20–30% contingency on top of the regulatory plan. The plan will slip. Non-conformities will arise. A test will fail and need repeat. A CER revision will add a month. A standard will be superseded. If you raised exactly to plan, every slip kills you. If you raised plan plus 25%, slips become inconvenient instead of fatal.

5. Model team burn against regulatory milestones, not against the calendar. When you hit a six-week delay in NB review, your team still burns. The burn does not politely pause. Model burn against the critical path, and assume the critical path has slack.

6. Sequence revenue-generating activities that do not require CE mark. Some early commercial activity is possible before CE under specific legal frames. Research use, collaboration agreements, compassionate use in specific cases, development contracts with large MedTech partners. None of these replace post-CE revenue, but they can moderate the cash trough. Confirm legality in your specific jurisdiction with counsel. These are narrow exceptions, not loopholes, and they must never cross into placing a device on the market under Article 5 before conformity is demonstrated.

7. Set treasury trigger points. Decide in advance: at what cash balance do you start bridge financing conversations? At what cash balance do you pause non-critical spend? At what cash balance do you stop the project and have an honest conversation with investors? Founders who decide these triggers in advance act rationally. Founders who decide them in the moment panic.

8. Update the cash flow map monthly. The map is a living document. Every time an NB invoice lands, a lab quote changes, or a team member is hired, the map updates. Treasury review is a 30-minute standing meeting, not an annual planning exercise.

Reality Check

  1. Do you have a 24-month cash flow map with every NB, lab, and consultant invoice mapped to the month it is expected?
  2. Have you read your Notified Body fee schedule and entered each line into the cash flow map?
  3. What percentage contingency did you raise on top of your regulatory plan, and is that percentage documented in your board materials?
  4. If your NB audit slips by eight weeks, at what cash balance do you start a bridge conversation?
  5. Are your test lab and CRO payment terms modelled accurately or copied from the quote without timing analysis?
  6. Is your team burn modelled against the critical path of the regulatory plan or against the calendar?
  7. Do you have a written treasury trigger policy with specific balance thresholds and actions?
  8. When was the last time you updated the cash flow map. This month, last quarter, or when you raised?

Frequently Asked Questions

How much contingency should a MedTech startup hold against regulatory spend? 20–30% on top of the nominal regulatory plan is a realistic starting point. Higher for first-time founders or novel device categories where the path is less predictable.

When do Notified Body fees start? Typically at application, with a deposit due before the NB starts work. Additional milestones trigger at Stage 1 audit, Stage 2 audit, technical documentation review, and certificate issuance. Annual surveillance fees continue for the life of the certificate under Article 52(3).

Can we delay NB fees to after first revenue? No. Notified Bodies are commercial entities and they invoice on their own schedule, not yours. Some may negotiate payment plans for deposits, but nobody is going to wait until you have CE mark and cash flow.

What is the single most common cash management mistake? Treating regulatory spend as calendar-linear. It is not. It is lumpy and milestone-driven. A flat monthly budget line hides the real cash trough.

Is non-dilutive funding a good solution for the cash trough? It can help. EU and national grant programmes can cover specific regulatory costs. But grants have their own timing. Reimbursement often lags spend by months. So they do not replace working capital, they supplement it.

Should we pay for expedited NB review? Some NBs offer expedited pathways at premium fees. The math depends on your burn rate. If your team burn is EUR 100,000/month and expediting saves three months, paying EUR 80,000 for expedited review is obvious. Run the math.

Sources

  1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 5, Article 52, Annex IX.
  2. EN ISO 13485:2016+A11:2021. Medical devices. Quality management systems. Requirements for regulatory purposes.
  3. EN ISO 10993-1:2025. Biological evaluation of medical devices.